Podolecki Tomasz, Lenarczyk Radoslaw, Kowalczyk Jacek, Jedrzejczyk-Patej Ewa, Chodor Piotr, Mazurek Michal, Francuz Pawel, Streb Witold, Mitrega Katarzyna, Kalarus Zbigniew
Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center of Heart Diseases, Zabrze, Poland.
Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center of Heart Diseases, Zabrze, Poland.
Am J Cardiol. 2018 Apr 1;121(7):805-809. doi: 10.1016/j.amjcard.2017.12.036. Epub 2018 Jan 12.
The aim of the study was to assess the clinical significance of complex ventricular arrhythmias (VAs) (sustained ventricular tachycardia [sVT] and ventricular fibrillation [VF]) in patients with ST-segment elevation myocardial infarction (STEMI) depending on timing of arrhythmia. We analyzed 4,363 consecutive patients with STEMI treated invasively between 2004 and 2014. The median follow-up was 69.6 months (range: 0 to 139.8 months). The study population was divided into 2 main groups; VA group encompassed 476 patients (10.91%) with VAs, whereas 3,887 subjects (89.09%) without VT or VF were included into the control group. In VA population, prereperfusion VA (34.24%; n = 163) was the most common arrhythmia, whereas reperfusion-induced, early postreperfusion, and late postreperfusion VAs were diagnosed in 103 (21.64%), 103 (21.64%), and 107 (22.48%) patients, respectively. Every type of sVT or VF complicating STEMI portended significantly worse in-hospital prognosis, however a late onset arrhythmia was associated with the highest (over fivefold) and reperfusion-induced VA with the lowest (less than threefold) increase in mortality risk compared with the control group. On the contrary, long-term mortality was significantly increased only in subjects with late postreperfusion and prereperfusion VAs compared with VA-free population (43.93% and 36.81%, respectively vs 22.58%; p <0.001). Apart from cardiogenic shock on admission, late postreperfusion (hazard ratio 3.39) and prereperfusion VAs (hazard ratio 2.76) were the strongest independent predictors of death in the analyzed population. In conclusion, 1 in 10 patients with STEMI treated invasively was affected by sVT or VF. The clinical impact of VAs was strongly dependent on timing of arrhythmia.
本研究的目的是根据心律失常的发生时间,评估ST段抬高型心肌梗死(STEMI)患者中复杂室性心律失常(VAs,持续性室性心动过速[sVT]和室颤[VF])的临床意义。我们分析了2004年至2014年间连续4363例接受侵入性治疗的STEMI患者。中位随访时间为69.6个月(范围:0至139.8个月)。研究人群分为两个主要组;VA组包括476例(10.91%)发生VAs的患者,而3887例(89.09%)无VT或VF的受试者被纳入对照组。在VA人群中,再灌注前VA(34.24%;n = 163)是最常见的心律失常,而再灌注诱导的、再灌注早期和再灌注晚期VA分别在103例(21.64%)、103例(21.64%)和107例(22.48%)患者中被诊断出。每种类型的sVT或VF并发STEMI均预示着院内预后明显更差,然而与对照组相比,晚期发生的心律失常与最高(超过五倍)的死亡风险增加相关,而再灌注诱导的VA与最低(不到三倍)的死亡风险增加相关。相反,与无VA人群相比,仅再灌注晚期和再灌注前VA患者的长期死亡率显著增加(分别为43.93%和36.81%,而无VA人群为22.58%;p <0.001)。除入院时的心源性休克外,再灌注晚期(风险比3.39)和再灌注前VA(风险比2.76)是分析人群中死亡的最强独立预测因素。总之,每10例接受侵入性治疗的STEMI患者中有1例受sVT或VF影响。VAs的临床影响强烈依赖于心律失常的发生时间。